Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Vizsgálat
SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease
2027. máj. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
CKM For Safe Use of SGLT2i in Type 1 Diabetes
2027. ápr. 1.· PHASE3 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation
2027. jan. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Evaluating SGLT2 Inhibitors for the Reduction of No-Reflow Phenomenon in Patients Undergoing PCI
2027. jan. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Canagliflozin Plus Progestin for Atypical Endometrial Hyperplasia and Early-Stage Endometrial Cancer
2027. jan. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Evaluation of Dapagliflozin and Empagliflozin as Adjunctive Therapy to Methotrexate in Patients With Rheumatoid Arthritis
2026. dec. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Adding Acetazolamide on Top of SGLT2 Inhibition in Persons With Type 2 Diabetes
2026. dec. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Discontinuation or Continuation of SGLT-2 Inhibitors Before Cardiac Surgery
2026. dec. 1.· PHASE4 · NOT_YET_RECRUITING· CTGOV
Publikáció
SGLT2 inhibitor and fibrosis progression in MASLD: Correspondence to letter to the editor on "Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediate fibrosis".
2026. nov. 6.· Clinical and molecular hepatology· PUBMED
Publikáció
Direct cardiac or systemic? Reexamining the cardiovascular mechanisms of SGLT2 inhibitors and GLP-1 receptor agonists.
2026. nov. 5.· Journal of basic and clinical physiology and pharmacology· PUBMED
Publikáció
Outcomes of SGLT2-inhibitor-induced euglycaemic diabetic ketoacidosis in a North Queensland intensive care unit: A retrospective cohort study.
2026. nov. 5.· Anaesthesia and intensive care· PUBMED
Publikáció
Design principles for natural SGLT2 modulators from multi-scale computation.
2026. nov. 4.· Royal Society open science· PUBMED
Publikáció
SGLT2 Inhibitors in Geriatric Heart Failure: Evidence, Safety, and Clinical Implementation.
2026. nov. 3.· Current heart failure reports· PUBMED
Publikáció
Comparative effects of SGLT2 inhibitors, pioglitazone, DPP-4 inhibitors, and sulfonylureas on dementia risk in type 2 diabetes.
2026. nov. 3.· The journal of prevention of Alzheimer's disease· PUBMED
Publikáció
Multi-organ proteomics identifies oxidative stress pathways underlying genetic and pharmacological SGLT2 suppression.
2026. nov. 3.· Redox biology· PUBMED
Vizsgálat
Clinical Decision Support for SGLT2i After AKI in Type 2 Diabetes
2026. nov. 2.· NA · RECRUITING· CTGOV
Publikáció
SGLT2 inhibitors in chronic kidney disease.
2026. nov. 2.· Postgraduate medicine· PUBMED
Publikáció
Implications of SGLT2 Inhibitors, GLP-1RAs, and Nonsteroidal MRAs on the Anticipated Burden of Heart Failure.
2026. nov. 2.· JACC. Heart failure· PUBMED
Publikáció
Influence of the PROFUND index on the effectiveness of SGLT2 inhibitors in elderly pluripathological patients with acute heart failure: PROFUND-IC registry.
2026. nov. 2.· Medicina clinica· PUBMED
Publikáció
Real-World Comparison of Cardiorenal Outcomes With SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists in Type 2 Diabetes.
2026. nov. 2.· Diabetes, obesity & metabolism· PUBMED
Vizsgálat
A Study of VCT220 Tablets in Adults With Type 2 Diabetes and Inadequate Blood Glucose Control
2026. nov. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publikáció
Severe Infection Outcomes With SGLT2 Versus DPP-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Active-Comparator Meta-Analysis of Real-World Cohorts.
2026. nov. 1.· Endocrinology, diabetes & metabolism· PUBMED
Publikáció
Effects of SGLT-2 Inhibitors on Plasma Concentrations and Renal Clearance of the Risk Marker Trimethylamine-N-Oxide in Patients With Type-2 Diabetes.
2026. nov. 1.· Endocrinology, diabetes & metabolism· PUBMED
Publikáció
Cardiovascular-kidney-metabolic syndrome: conceptual framework, clinical implications, and therapeutic perspectives with a focus on SGLT2 inhibitors.
2026. nov. 1.· Postgraduate medicine· PUBMED
Publikáció
Challenge-Oriented Decision Tree for Analytical Method Selection in Metformin, Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Triple Antidiabetic Fixed-Dose Combinations in Pharmaceutical Dosage Forms.
2026. nov. 1.· Biomedical chromatography : BMC· PUBMED
Publikáció
Association of GLP-1 receptor agonist and SGLT2 inhibitor use with outcomes in patients with type 2 diabetes undergoing pacemaker implantation.
2026. nov. 1.· Current problems in cardiology· PUBMED
Publikáció
Baseline monocyte SGLT2 mRNA expression and changes in the fibrosis-4 index after luseogliflozin treatment in participants with type 2 diabetes and MASLD.
2026. okt. 31.· Diabetology international· PUBMED
Publikáció
SGLT2 inhibitor-induced genitourinary infections and the consequent antimicrobial-antidiabetic drug interactions: A narrative review of clinical and pharmacovigilance concern.
2026. okt. 31.· Diabetes research and clinical practice· PUBMED
Publikáció
Deciphering the neuroprotective signaling of SGLT2 inhibitors in Alzheimer's disease.
2026. okt. 30.· Journal of Alzheimer's disease : JAD· PUBMED
Publikáció
Haematological and iron-handling effects of SGLT2 inhibitors: a meta-analysis of randomised trials.
2026. okt. 30.· Heart (British Cardiac Society)· PUBMED